PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 23585572-1 2013 We used site-directed labeling of the type 1 ryanodine receptor (RyR1) and fluorescence resonance energy transfer (FRET) measurements to map RyR1 sequence elements forming the binding site of the 12-kDa binding protein for the immunosuppressant drug, FK506. Tacrolimus 251-256 ryanodine receptor 1 Homo sapiens 141-145 22328519-0 2012 Disparities in the association of the ryanodine receptor and the FK506-binding proteins in mammalian heart. Tacrolimus 65-70 ryanodine receptor 1 Homo sapiens 38-56 22386321-2 2012 Besides immunosuppression, tacrolimus has been reported to have the potential to increase muscle strength by enhancing ryanodine receptor (RyR) function. Tacrolimus 27-37 ryanodine receptor 1 Homo sapiens 119-137 22386321-2 2012 Besides immunosuppression, tacrolimus has been reported to have the potential to increase muscle strength by enhancing ryanodine receptor (RyR) function. Tacrolimus 27-37 ryanodine receptor 1 Homo sapiens 139-142 22386321-3 2012 However, few attempts have been made to demonstrate the early effect of tacrolimus as an RyR enhancer in clinical investigation. Tacrolimus 72-82 ryanodine receptor 1 Homo sapiens 89-92 22386321-14 2012 SIGNIFICANCE: This early effect of tacrolimus may imply a pharmacological enhancement of RyR function to improve E-C coupling in MG. Tacrolimus 35-45 ryanodine receptor 1 Homo sapiens 89-92 17307394-6 2007 Among MG patients, the mean ECCT was longer for patients with thymoma than for those without it (P=0.04), and was shorter for patients treated with FK506 (an immunosuppressant and also an enhancer of RyR related Ca(2+) release) than for those not receiving this treatment (p=0.04). Tacrolimus 148-153 ryanodine receptor 1 Homo sapiens 200-203 21860784-8 2011 The pharmacological treatment does not differ from nonthymoma MG, except for tacrolimus which is an option in difficult thymoma and nonthymoma MG cases with RyR antibodies. Tacrolimus 77-87 ryanodine receptor 1 Homo sapiens 157-160 19785652-6 2009 KEY RESULTS: FK506 which displaces FKBP from each receptor (to inhibit calcineurin) increased the [Ca(2+)](cyto) rise evoked by activation of either RyR or IP(3)R. Tacrolimus 13-18 ryanodine receptor 1 Homo sapiens 149-152 16405911-2 2006 Removal of FKBP12 using FK506 or rapamycin causes an increased open probability and an increase in the frequency of sub-conductance states in RyR1. Tacrolimus 24-29 ryanodine receptor 1 Homo sapiens 142-146 16405911-7 2006 The orientation of RyR1-bound FKBP12, with part of its FK506 binding site facing towards RyR1, allows us to propose how FK506 is involved in the dissociation of FKBP12 from RyR1. Tacrolimus 55-60 ryanodine receptor 1 Homo sapiens 19-23 16405911-7 2006 The orientation of RyR1-bound FKBP12, with part of its FK506 binding site facing towards RyR1, allows us to propose how FK506 is involved in the dissociation of FKBP12 from RyR1. Tacrolimus 120-125 ryanodine receptor 1 Homo sapiens 19-23 16405911-7 2006 The orientation of RyR1-bound FKBP12, with part of its FK506 binding site facing towards RyR1, allows us to propose how FK506 is involved in the dissociation of FKBP12 from RyR1. Tacrolimus 120-125 ryanodine receptor 1 Homo sapiens 89-93 16405911-7 2006 The orientation of RyR1-bound FKBP12, with part of its FK506 binding site facing towards RyR1, allows us to propose how FK506 is involved in the dissociation of FKBP12 from RyR1. Tacrolimus 120-125 ryanodine receptor 1 Homo sapiens 89-93 16637922-5 2006 The immunosuppressant (FK506), which enhances Ca(2+) release from the RyR, seems to have a symptomatic effect on MG patients with RyR antibodies. Tacrolimus 23-28 ryanodine receptor 1 Homo sapiens 70-73 16637922-5 2006 The immunosuppressant (FK506), which enhances Ca(2+) release from the RyR, seems to have a symptomatic effect on MG patients with RyR antibodies. Tacrolimus 23-28 ryanodine receptor 1 Homo sapiens 130-133 15159506-3 2004 In a preliminary open trial with FK506, immunosuppressant and enhancer of RyR-related sarcoplasmic calcium release, the authors observed the sustained benefits in anti-RyR-positive MG patients. Tacrolimus 33-38 ryanodine receptor 1 Homo sapiens 168-171 15955561-1 2005 FK506 and rapamycin are immunosuppressant drugs that disrupt the interaction of FK506-binding proteins (FKBPs) with ryanodine receptors (RyR1), which form homotetrameric Ca2+ release channels in the sarcoplasmic reticulum (SR) of skeletal muscle. Tacrolimus 0-5 ryanodine receptor 1 Homo sapiens 137-141 15955561-1 2005 FK506 and rapamycin are immunosuppressant drugs that disrupt the interaction of FK506-binding proteins (FKBPs) with ryanodine receptors (RyR1), which form homotetrameric Ca2+ release channels in the sarcoplasmic reticulum (SR) of skeletal muscle. Tacrolimus 80-85 ryanodine receptor 1 Homo sapiens 137-141 11437371-4 2001 Ascomycin, an FK506 analogue, was identified for the first time as a drug which can disrupt the FKBP12-RyR1 complex. Tacrolimus 14-19 ryanodine receptor 1 Homo sapiens 103-107 12871170-2 2003 The 565 kDa RyR protein forms a tetrameric channel that is part of a macromolecular signaling complex that also includes four FK506 binding proteins (FKBPs). Tacrolimus 126-131 ryanodine receptor 1 Homo sapiens 12-15 15118362-8 2004 In addition, this SAM-induced increase in RyR/Ca(2+) channel activity was blocked by 30 microM ryanodine and by FK506 (100 microM), a ligand for the RyR accessory protein. Tacrolimus 112-117 ryanodine receptor 1 Homo sapiens 42-45 15118362-8 2004 In addition, this SAM-induced increase in RyR/Ca(2+) channel activity was blocked by 30 microM ryanodine and by FK506 (100 microM), a ligand for the RyR accessory protein. Tacrolimus 112-117 ryanodine receptor 1 Homo sapiens 149-152 14532276-2 2003 Abnormally high phosphorylation levels (hyperphosphorylation) at Ser-2843 in RyR1 and Ser-2809 in RyR2 and dissociation of FK506-binding proteins from the receptors have been implicated as one of the causes of altered calcium homeostasis observed during human heart failure. Tacrolimus 123-128 ryanodine receptor 1 Homo sapiens 77-81 11557049-4 2001 Furthermore, of the proteins solubilised from skeletal muscle, cardiac muscle and brain microsomes, only skeletal muscle RyR1 bound to an FKBP12-glutathione-S-transferase fusion protein, in a high affinity FK506 displaceable manner. Tacrolimus 206-211 ryanodine receptor 1 Homo sapiens 121-125 10856121-11 2000 In conclusion, FK506 inhibited active Ca2+ uptake by the SERCA Ca2+ pump; in addition, FK506 enhanced intracellular Ca2+ release through the RyR, but it had no direct effect on IP3-induced Ca2+ release. Tacrolimus 87-92 ryanodine receptor 1 Homo sapiens 141-144 10781282-3 2000 The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine. Tacrolimus 28-33 ryanodine receptor 1 Homo sapiens 120-140 10781282-3 2000 The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine. Tacrolimus 28-33 ryanodine receptor 1 Homo sapiens 187-207 10781282-3 2000 The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine. Tacrolimus 35-45 ryanodine receptor 1 Homo sapiens 120-140 10781282-3 2000 The immunosuppressant drugs FK506 (tacrolimus) and rapamycin can promote dissociation of FK506 binding protein from the ryanodine receptor 1 and by this mechanism increase sensitivity of ryanodine receptor 1 to agonists such as caffeine. Tacrolimus 35-45 ryanodine receptor 1 Homo sapiens 187-207 7531689-2 1995 FKBP-12 (FKBP), the soluble receptor for the immunosuppresant drug FK-506, is tightly bound to the calcium release channel (CRC)/ryanodine receptor (RyR) of skeletal muscle terminal cisternae (TC) of sarcoplasmic reticulum with a stoichiometry of 4 mol of FKBP per tetrameric RyR complex. Tacrolimus 67-73 ryanodine receptor 1 Homo sapiens 149-152